Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History PSNL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics PSNL

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Personalis Inc

PSNL
Current price
7.45 USD -0.15 USD (-1.97%)
Last closed 7.51 USD
ISIN US71535D1063
Sector Healthcare
Industry Diagnostics & Research
Exchange NASDAQ
Capitalization 658 022 016 USD
Yield for 12 month +393.38 %
1Y
3Y
5Y
10Y
15Y
PSNL
21.11.2021 - 28.11.2021

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California. Address: 6600 Dumbarton Circle, Fremont, CA, United States, 94555

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

7.00 USD

P/E Ratio

Dividend Yield

Financials PSNL

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures PSNL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+84 614 000 USD

Last Year

+73 481 000 USD

Current Quarter

+20 605 000 USD

Last Quarter

+16 800 000 USD

Current Year

+26 825 000 USD

Last Year

+18 208 000 USD

Current Quarter

+7 207 000 USD

Last Quarter

+4 550 000 USD
EBITDA -56 392 000 USD
Operating Margin TTM -85.88 %
Price to Earnings
Return On Assets TTM -17.90 %
PEG Ratio
Return On Equity TTM -51.25 %
Wall Street Target Price 7.00 USD
Revenue TTM 85 694 000 USD
Book Value 2.35 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 5.50 %
Dividend Yield
Gross Profit TTM 28 539 000 USD
Earnings per share -1.29 USD
Diluted Eps TTM -1.29 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -98.10 %

Stock Valuation PSNL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 6.03
Price Sales TTM 7.68
Enterprise Value EBITDA -0.028
Price Book MRQ 3.17

Technical Indicators PSNL

For 52 Weeks

1.41 USD 7.79 USD
50 Day MA 5.21 USD
Shares Short Prior Month 3 875 344
200 Day MA 4.74 USD
Short Ratio 5.55
Shares Short 3 862 297
Short Percent 6.33 %